What’s Next For The International Pricing Index? Parsing A Strange US Senate Vote
Senate Finance drug pricing bill is moving forward, with two critical amendments defeated by 14-14 tie votes. One would have stripped the inflation penalty from the bill, which probably would have killed any bipartisan momentum. The second targeted the Medicare Part B International Pricing Index and was defeated by a truly surprising set of votes.
You may also be interested in...
Outgoing BIO CEO Focuses On Out-Of-Pocket Costs As Solution To Drug Pricing Woes
In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.
International Pricing Index Could Suffer From Industry Gaming
Former US FDA commissioner Scott Gottlieb doesn't "want to give too much away," but expresses skepticism about Trump administration's ability to implement its international price index proposal, noting there are ways for brand companies to game the system.
House Draft Drug Pricing Bill Offers Aggressive Policies But Near-Term Prospects Look Weak
If nothing else, the purported draft may be a preview of what Democrats might do if they prevail in 2020. Proposal calls for HHS price negotiation, international reference pricing, price inflation rebates and structural Medicare Part D changes.